



OPEN ACCESS

EXTENDED REPORT

Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism

Cristina Municio,¹ Ángeles Domínguez-Soto,² Sara Fuentelsaz-Romero,¹ Amalia Lamana,³ Nuria Montes,³ Víctor D Cuevas,² Raquel García Campos,¹ José L Pablos,⁴ Isidoro González-Álvaro,³ Amaya Puig-Kröger¹

Handling editor Josef S Smolen

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2017-212537>).

¹Laboratorio de Inmuno-Metabolismo, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

²Centro de Investigaciones Biológicas, Madrid, Spain

³Servicio de Reumatología, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Hospital Universitario La Princesa, Madrid, Spain

⁴Servicio de Reumatología, Instituto de Investigación Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain

Correspondence to

Dr Amaya Puig-Kröger, Laboratorio de Inmuno-Metabolismo, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; amaya.puig@salud.madrid.org

CM and ÁD-S contributed equally.

Received 15 October 2017
Revised 21 December 2017
Accepted 15 January 2018
Published Online First
3 February 2018



To cite: Municio C, Domínguez-Soto Á, Fuentelsaz-Romero S, et al. *Ann Rheum Dis* 2018;**77**:752–759.

ABSTRACT

Objectives Methotrexate (MTX) is the anchor drug for treatment of rheumatoid arthritis (RA), but the mechanism of its anti-inflammatory action is not fully understood. In RA, macrophages display a proinflammatory polarisation profile that resembles granulocyte-macrophage colony-stimulating factor (GM-CSF)-differentiated macrophages and the response to MTX is only observed in thymidylate synthase⁺ GM-CSF-dependent macrophages. To determine the molecular basis for the MTX anti-inflammatory action, we explored toll-like receptor (TLR), RA synovial fluid (RASf) and tumour necrosis factor receptor (TNFR)-initiated signalling in MTX-exposed GM-CSF-primed macrophages.

Methods Intracellular responses to TLR ligands, TNF α or RASf stimulation in long-term low-dose MTX-exposed human macrophages were determined through quantitative real-time PCR, western blot, ELISA and siRNA-mediated knockdown approaches. The role of MTX in vivo was assessed in patients with arthritis under MTX monotherapy and in a murine sepsis model.

Results MTX conditioned macrophages towards a tolerant state, diminishing interleukin (IL)-6 and IL-1 β production in LPS, LTA, TNF α or RASf-challenged macrophages. MTX attenuated LPS-induced MAPK and NF- κ B activation, and toll/IL-1R domain-containing adaptor inducing IFN-beta (TRIF1)-dependent signalling. Conversely, MTX increased the expression of the NF- κ B suppressor A20 (*TNFAIP3*), itself a RA-susceptibility gene. Mechanistically, MTX-induced macrophage tolerance was dependent on A20, as siRNA-mediated knockdown of A20 reversed the MTX-induced reduction of IL-6 expression. In vivo, *TNFAIP3* expression was significantly higher in peripheral blood cells of MTX-responsive individuals from a cohort of patients with arthritis under MTX monotherapy, whereas MTX-treated mice exhibited reduced inflammatory responses to LPS.

Conclusions MTX impairs macrophage proinflammatory responses through upregulation of A20 expression. The A20-mediated MTX-induced innate tolerance might limit inflammation in the RA synovial context, and positions A20 as a potential MTX-response biomarker.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that primarily affects synovial joints. Predominant cytokines in RA pathogenesis are TNF α , interleukin (IL)-6 and IL-1 β ,

which are mainly produced by macrophages and act locally and systemically.^{1–3} In fact, macrophages accumulate in the synovium of RA joints, where they exhibit destructive and remodelling potential and contribute considerably to inflammation and joint destruction.⁴ Importantly, reduction in the number of macrophages in the synovium constitutes a biomarker for response to treatment in patients with RA.⁵

GM-CSF induces macrophage differentiation from haematopoietic progenitor cells and is a key driver of tissue inflammation.⁶ GM-CSF was one of the first cytokines detected in human synovial fluid from inflamed joints and several lines of data suggest that GM-CSF strongly influences the development and pathogenesis of RA.⁶ GM-CSF-deficient mice are protected from developing collagen-induced arthritis and blockade of GM-CSF reduces the severity of established disease in wild-type mice, thus supporting a key role for GM-CSF in the initiation and development of inflammatory arthritis. Moreover, overexpression or injection of GM-CSF is associated with flares of arthritis and patients receiving GM-CSF after chemotherapy showed exacerbation of established RA.⁷ In line with all the above findings, macrophages from patients with active RA display a transcriptomic and phenotypical proinflammatory polarisation profile that resembles GM-CSF-differentiated macrophages.⁸ According to the role of GM-CSF in RA, phase I and II clinical trials targeting GM-CSF or GM-CSF receptor- α in RA have shown rapid and sustained clinical responses without major safety concerns.^{9–11}

The folic acid antagonist methotrexate (MTX) is the disease modifying anti-rheumatic drug of first choice in the treatment of early and established RA, and shows good efficacy, with 40% of patients with RA achieving an American College of Rheumatology score 50 (ACR50) response.^{12,13} MTX blocks different enzymes of the folate or one-carbon metabolism. While MTX blocks dihydrofolate reductase, polyglutamated MTX potently inhibits thymidylate synthase (TS), and both enzymes are crucial for the de novo biosynthesis of purines and pyrimidines required for DNA replication and cellular proliferation.¹³ In patients with RA, MTX treatment is associated with a significant decrease in serum IL-6 and IL-8.¹⁴ However, despite the beneficial effect of MTX in current RA therapies, its mechanism of action as an anti-inflammatory drug remains inconclusive. Different cellular-specific mechanisms have been proposed to explain the inhibition of NF- κ B,

the central regulator of proinflammatory cytokine gene expression. Previous studies on T lymphocytes and fibroblast-like synoviocytes have found that MTX inhibits NF- κ B activity via tetrahydrobiopterin (BH₄) depletion, lincRNA-p21 increase or adenosine receptor activation, respectively.^{15 16} Although MTX restores NF- κ B activity in peripheral blood mononuclear cells (PBMCs) from patients with RA,¹⁵ no information is available on the effect of clinical doses of MTX on NF- κ B in human macrophages, whose transcriptome is significantly modulated after low-dose MTX exposure.¹⁷

We have also previously described that MTX exclusively targets proinflammatory TS⁺ GM-CSF-primed macrophages.¹⁷ In an attempt to determine the molecular mechanism underlying the anti-inflammatory actions of MTX, we have explored the inflammatory response of MTX-exposed GM-CSF-primed macrophages. We now report that long-term low-dose MTX treatment modifies macrophage response to TLR ligands or TNF α stimulation by increasing *TNFAIP3* (A20) expression in macrophages, and that MTX conditions macrophages for impaired responses towards pathogen agents like LPS, TNF α or RA synovial fluid (RASf).

METHODS

Detailed methods are supplied in the online supplementary file.

Human PBMCs were isolated from buffy coats from normal donors. Monocytes were purified from PBMCs by magnetic cell sorting using CD14 microbeads (Miltenyi) and were cultured at 0.5×10^6 cells/mL for 7 days in Roswell Park Memorial Institute (RPMI) supplemented with 10% fetal calf serum, and containing GM-CSF (1000 U/mL) to generate GM-CSF-polarised macrophages (GM-M ϕ). Independent preparations of monocytes were unexposed or exposed once to MTX (50 nM)^{18 19} and differentiated to GM-M ϕ for 7 days. MTX is a drug given weekly to patients with RA and we followed in vitro the patient schedule.¹² LPS (10 ng/mL, 01111:B4 strain), LTA (5 μ g/mL), TNF α (20 ng/mL) and RASf were added for the indicated time points to 7-day fully differentiated GM-M ϕ and were analysed by quantitative real-time RT-PCR, immunoblotting or ELISA. RASf were obtained from patients with active knee arthritis, confirmed by a highly cellular synovial fluid, and were heterogeneous regarding demographic, disease characteristics and previous RA therapy. For in vivo MTX-cross tolerance, C57BL/6J mice between 6 and 8 weeks of age (n=6 mice/group) received phosphate-buffered saline (PBS) or MTX intraperitoneally (2 mg/kg). Seven days later, intraperitoneal LPS (9 mg/kg) was administered and serum collected after 4 hours for IL-6 and TNF α determination by ELISA. Patients with early arthritis in MTX monotherapy were recruited from the Princesa Early Arthritis Register Longitudinal study. Informed consent is received from the patient.²⁰ Statistical analysis was performed using paired Student's t-test and a P value <0.05 was considered significant (*P<0.05, **P<0.01, ***P<0.001).

RESULTS

Long-term low-dose MTX treatment diminishes LPS, LTA, TNF α and RASf-induced proinflammatory cytokine production in human macrophages

A variety of TLR ligands, either endogenous or of microbial origin, are present within RA synovia.²¹ To determine the role of MTX on macrophage TLR4 activation, monocytes were exposed to a single dose of MTX before initiation of the GM-CSF-driven differentiation process, and later challenged with LPS at the 7-day culture (figure 1A). MTX pretreatment diminished

LPS-induced IL-6 expression at the mRNA and protein levels (figure 1B). Similarly, MTX pretreatment reduced LPS-induced TNF α , IL-12p40 and IL-1 β production although with different kinetics (figure 1C and online supplementary figure S1). By contrast, the expression of other LPS-responsive macrophage genes²² was either unaltered (*IFIT2*, *PKIG*) or increased (*CCR7*) on MTX pretreatment (online supplementary figure S1), thus indicating that proinflammatory cytokine production is selectively inhibited in MTX-exposed macrophages. The specificity of MTX to attenuate LPS-dependent proinflammatory cytokine production in macrophages was analysed in the presence of folinic acid (FA). FA restored LPS-induced IL-6 secretion in MTX-treated macrophages, indicating that MTX-induced effects are mediated through blocking the one-carbon metabolism (figure 1D). Similar to TLR4 activation, MTX-treated macrophages exhibited a lower level of LTA-dependent IL-6 and IL-1 β gene expression and protein secretion (figure 1E). More importantly, analogous findings were observed when macrophages were challenged with TNF α , the predominant inflammatory cytokine found in RA joints¹: MTX-treated macrophages exhibited a lower expression of TNF α -induced *IL6* and *IL1B* mRNA and IL-6 and IL-12p40 secretion than untreated macrophages (figure 1F), thus indicating that MTX attenuates proinflammatory cytokine expression in response to TLR4 and TLR2 ligands as well as after TNF α stimulation.

Finally, to determine whether MTX-exposed macrophages are also refractory to the effect of the RA synovial environment, MTX-treated macrophages were exposed to RASf from patients with active disease. RASf-induced *IL6* mRNA was attenuated in MTX-treated macrophages although the effect of MTX differed among tested RASf (figure 2). Altogether, these results indicate that MTX diminishes the production of RA-associated cytokines in human macrophages exposed to stimuli known to be present in RA joints (TLR2 and TLR4 ligands, TNF α and RASf).

TNFAIP3 is an MTX response gene and is involved in MTX-induced tolerance in macrophages

The above results suggested that low-dose MTX renders macrophages less responsive to a subsequent stimulation by proinflammatory stimuli and that MTX might impose a state of desensitisation in macrophages that resembles the 'LPS tolerance' phenomenon.²³ Interestingly, and in line with the potential acquisition of a tolerance state in MTX-treated macrophages, Gene Set Enrichment Analysis (GSEA) on the transcriptome of MTX-treated macrophages (GSE71253) revealed that long-term MTX treatment promotes a significant upregulation of the 'TNF α signalling via NF- κ B' (false discovery rate (FDR) q value=0.0001) and 'inflammatory response' (FDR q value=0.0001) gene sets (figure 3A).^{17 24} In agreement with the GSEA prediction, MTX-treated monocytes led to the generation of macrophages with a significantly higher *IL1B*, *IL1A* and *IL6* mRNA expression (figure 3B).

To address whether MTX promotes 'bona fide' innate tolerance in macrophages, and since tolerant cells exhibit a lower level of MAPK and NF- κ B activation on TLR stimulation,^{23 24} we first determined the levels of LPS and TNF α -induced MAPK and I κ B α activation in MTX-treated macrophages. MTX pretreatment reduced the activation of p38 and jun amino-terminal kinase (JNK) in response to LPS and TNF α (figure 3C). Moreover, a higher level of I κ B α was detected in LPS and TNF α -exposed MTX-pretreated macrophages (figure 3C), indicating that the LPS and TNF α -induced activation of both MAPK and NF- κ B was impaired in MTX-treated macrophages. These results were




Figure 1 MTX alters TLR4, TLR2 and TNF α responsiveness in GM-CSF-primed macrophages. (A) Schematic representation of the experiments. Monocytes were exposed to 50 nM MTX at the beginning of the 7-day macrophage differentiation process with GM-CSF and challenged with LPS (10 ng/mL), LTA (5 μ g/mL) or TNF α (20 ng/mL) on day 7. Cells (GM-M ϕ) were assayed at time points poststimulation. (B) Expression of IL-6 by qRT-PCR (left) or ELISA (right) by monocytes differentiated with GM-CSF in the absence or presence of MTX and challenged with LPS for 48 hours. Mean \pm SEM of four independent donors are shown (* P <0.05, ** P <0.01). (C) Production of TNF α or IL-12p40 by monocytes differentiated with GM-CSF in the absence or presence of MTX and challenged with LPS for 48 hours. Mean \pm SEM of four independent donors are shown (* P <0.05, ** P <0.01). (D) Production of IL-6 by monocytes differentiated with GM-CSF in the absence or presence of MTX or FA (1 μ M) and challenged with LPS for the indicated time points, as determined by ELISA. Mean \pm SEM of three independent donors are shown (* P <0.05, ** P <0.01). (E–F) Expression of IL-6, IL-1 β and IL-12p40 by qRT-PCR (upper panels) or ELISA (lower panels) by monocytes differentiated with GM-CSF in the absence or presence of MTX and challenged with LTA (E) or TNF α (F) for the indicated time points. Mean \pm SEM of three (E) and five (F) independent donors are shown (* P <0.05). FA, folic acid; IL, interleukin; Mo, monocytes; MTX, methotrexate; qRT-PCR, quantitative real-time PCR.

further confirmed after analysis of the LPS-induced NF- κ B-dependent transcription (figure 3D), as MTX-treated macrophages exhibited lower LPS-induced NF- κ B-dependent transcriptional activity than untreated GM-M ϕ . Therefore, MTX treatment conditions macrophages for an impaired NF- κ B transcriptional activity after LPS stimulation. The TRIF-dependent pathway, implicated in mediating the type I interferon activation of the LPS signalling,²⁵ was also explored. Since MTX-treated cells exhibited lower C-X-C motif chemokine ligand 10 (CXCL10) secretion and phosphorylated signal transducer and activator of transcription 1 (p-Stat1) activation in response to LPS than untreated cells (figure 3E), MTX appears to exert its effects also via the TRIF pathway.

Next, we determined the expression of regulators of TLR-induced cytokine production that have been previously implicated in LPS tolerance.²³ Long-term MTX treatment significantly

increased the expression of *TNFAIP3*, decreased *TLR4* and *TLR2* and did not modulate *IRAK3* (IRAK-M), *INPP5D* (SHIP1), *SOCS1*, *SOCS3* and *PELI3* mRNA expression in GM-M ϕ (figure 3F).^{23 24 26 27} Reduction of *TLR2* and *TLR4* by MTX was modest at the mRNA level and not observed in all donors at the protein level (online supplementary figure S2). By contrast, *TNFAIP3* induction by MTX was observed in all donors examined. *TNFAIP3* codes the A20 protein, a ubiquitin-modifying enzyme that acts as a pivotal NF- κ B suppressor after TLRs or TNFR stimulation.²⁸ Kinetic studies revealed that *TNFAIP3* expression increased 5 days after MTX addition in GM-CSF-primed macrophages (figure 3G), thus suggesting a role for A20 in MTX-induced tolerance. To explore whether this is the case, we determined the effect of silencing *TNFAIP3* expression. siRNA-mediated *TNFAIP3* knockdown in MTX-treated GM-M ϕ significantly restored IL-6 secretion in response to




Figure 2 MTX diminishes RASF IL6 induction in GM-CSF-primed macrophages. Expression of *IL6* by quantitative real-time PCR by monocytes differentiated with GM-CSF in the absence or presence of MTX and challenged with 25% synovial fluid from patients with active RA (RASF) on day 7 for the indicated time points (* $P < 0.05$). Independent macrophage donors (nos 1–4) were challenged with RASF from two different patients with RA (donor no. 1 with RASF-A and donors no. 2, no. 3 and no. 4 with RASF-B). IL, interleukin; MTX, methotrexate; RA, rheumatoid arthritis; RASF, RA synovial fluid.

LPS, as macrophages with lower A20 expression yielded significantly higher levels of LPS-induced IL-6 (figure 3H). Therefore, MTX-induced A20 contributes to the reduced LPS-induced IL-6 expression seen in MTX-treated macrophages, suggesting its involvement in the MTX-induced tolerance.

MTX-dependent expression of *TNFAIP3* involves TS inhibition and TP53 activation

To explore the role of MTX on *TNFAIP3* expression, we first determined the sensitivity of the MTX-dependent *TNFAIP3* upregulation to FA. *TNFAIP3* induction by MTX was inhibited by the simultaneous addition of FA, indicating that MTX-triggered *TNFAIP3* induction relies on blocking one-carbon metabolism (figure 4A). However, FA in the clinic is usually prescribed 24 hours after MTX treatment.²⁹ As expected, FA did not reverse MTX-induced *TNFAIP3* expression when added 24 hours after MTX, showing that FA does not block the potential beneficial clinical effects of *TNFAIP3* induction by MTX in RA (figure 4B).

Unlike the rapid induction of A20 in response to inflammatory stimuli that takes place 30–60 min after NF- κ B activation,²⁸ a slow induction of A20 was observed in MTX-exposed macrophages (figure 3G). We have previously demonstrated that the mechanism involved in MTX response in proinflammatory macrophages relies on TS inhibition and p53 activation, what led us to assess whether the TS/p53 axis is involved in MTX-induced A20 expression.¹⁷ Assessment of the underlying mechanism revealed that MTX-triggered *TNFAIP3* induction in GM-M ϕ was significantly diminished (40%) after TS silencing with two different small interfering RNA (figure 4C), thus indicating that MTX-triggered *TNFAIP3* upregulation is partly dependent on TS expression. Moreover, knockdown of TS sufficed to increase *TNFAIP3* mRNA expression in GM-M ϕ , an effect that was prevented in the presence of the p53 inhibitor pifithrin- α (figure 4D). Therefore, MTX induces a tolerant state in macrophages by upregulating the expression of *TNFAIP3* in a TS/p53-dependent pathway.

MTX-induced tolerance in vivo

To address the relevance of the MTX-induced tolerance in vivo, mice were treated with MTX for 7 days, mimicking the patient schedule therapy currently in use,¹² and challenged with an intraperitoneal injection of LPS before determination of the serum concentrations of IL-6 and TNF α (figure 5A). LPS-induced serum IL-6 and TNF α significantly diminished in MTX-pretreated mice (figure 5B, C), whose white blood cell counts did not differ significantly from those of untreated mice (not shown). The same results

were obtained when MTX was injected once a week for 4 weeks (not shown). Therefore, and in agreement with its ability to limit macrophage responses to LPS in vitro, MTX is capable of inducing a state of tolerance in mice in vivo.

TNFAIP3 mRNA expression increases in early arthritis patients responders to MTX

To evaluate the association between MTX treatment and *TNFAIP3* expression in patients with arthritis, we determined *TNFAIP3* mRNA levels in PBMCs from patients with early arthritis at baseline and during 1 year of MTX monotherapy (see online supplementary table S1). We found that *TNFAIP3* mRNA expression levels tend to increase along the follow-up (figure 6A, model 1 in online supplementary table S2). Furthermore, *TNFAIP3* mRNA expression significantly increased only in those patients who respond to MTX therapy (figure 6B,C, model 2 and model 3 in online supplementary table S2). In fact, being or not an MTX responder explained 20% of the variability of *TNFAIP3* expression ($R^2 m = 0.196$, model 3 in online supplementary table S2). Altogether, these results indicate that *TNFAIP3* expression is higher in MTX responder patients with arthritis, suggesting that *TNFAIP3* might be an MTX responsiveness biomarker, although these findings require confirmation in larger cohorts.

DISCUSSION

Weekly administered MTX is the main starting therapy and the anchor drug for the treatment of RA, cutaneous psoriasis and psoriatic arthritis.³⁰ However, the exact mechanism underlying the anti-inflammatory actions of MTX remains not fully understood.¹³ We have previously shown that MTX triggers the acquisition of a proinflammatory gene profile in human GM-CSF-primed macrophages.¹⁷ We now report that long-term low-dose MTX conditions GM-CSF-primed macrophages towards a tolerance state that renders them less responsive to TLR ligands, TNF α and RASF stimulation. Mechanistically, MTX reduces LPS and TNF α -dependent MAPK activation, I κ B α degradation, NF- κ B activity and proinflammatory cytokine production in human macrophages. In addition, MTX increases A20 expression, a pivotal NF- κ B suppressor whose knockdown impairs the MTX-induced tolerance effect. In line with these findings, MTX-treated mice exhibit a reduced inflammatory response to LPS. Altogether, these results indicate that the global anti-inflammatory activity of MTX relies on its ability to induce a proinflammatory profile in GM-CSF-primed macrophages, making MTX-conditioned macrophages less responsive to proinflammatory stimuli. Our results reconcile the transcriptional¹⁷ and functional effects of MTX on human




Figure 3 MTX suppresses TLR4 and TNFR signalling and induces *TNFAIP3* (A20) in macrophages. (A) Gene Set Enrichment Analysis results for MTX-treated versus untreated macrophages for 7 days indicating the normalised enrichment score and the false discovery rate. (B) Relative expression of *IL1B*, *IL1A*, *IL6* and *TNFA* in MTX-treated (Mo+GM(MTX)) and untreated (Mo+GM) GM-CSF-primed macrophages (**P*<0.05, adjusted *P* value), as determined by microarray (left) and qRT-PCR (right). (C) Immunoblot analysis of pp38, pJNK and pERK, p38, JNK, extracellular signal-regulated kinase (ERK) and IκBα by monocytes differentiated with GM-CSF in the absence or presence of MTX for 7 days and challenged with LPS (left) or TNFα (right) for the indicated time points. A representative experiment of four independent donors is shown. (D) Basal and LPS-induced NF-κB-dependent transcriptional activity in MTX-treated and untreated GM-MØ. Mean±SEM of the relative NF-κB luciferase activity (compared with Renilla luciferase activity) of five independent experiments are shown (**P*<0.05). (E) Immunoblot analysis of pStat1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (left), and CXCL10 secretion (right) by monocytes differentiated with GM-CSF in the absence or presence of MTX for 7 days and challenged with LPS for 2 hours (left) or 24 hours (right). (F) Relative expression of the genes encoding molecules involved in tolerance (black, upregulated in LPS tolerance; white, downregulated in LPS tolerance) in MTX-treated (Mo+GM(MTX)) and untreated (Mo+GM) GM-CSF-primed macrophages (**P*<0.05, adjusted *P* value). (G) Expression of *TNFAIP3* by monocytes differentiated with GM-CSF in the absence or presence of MTX, as determined by qRT-PCR. Mean±SEM of three independent donors are shown (**P*<0.05, ****P*<0.001). Immunoblot analysis of A20 and GAPDH in monocytes differentiated with GM-CSF in the presence of MTX at the indicated time points. (H) Monocytes differentiated with GM-CSF in the absence or presence of MTX for 5 days were transfected with control siRNA (siC) or siRNA for A20 (siA20) and 48 hours later, cells were then stimulated with LPS for 3 hours, and expression levels of A20, GAPDH (immunoblot) and IL-6 (ELISA) were detected. IL, interleukin; Mo, monocytes; MTX, methotrexate; qRT-PCR, quantitative real-time PCR.




Figure 4 MTX-dependent expression of *TNFAIP3*. *TNFAIP3* expression by monocytes differentiated with GM-CSF in the absence or presence of MTX (50 nM), FA or both, as determined by qRT-PCR. In (A), FA (1 μ M) was added simultaneously with MTX and in (B) FA (50 nM, concentration of FA found in the serum of patients with RA) was added 24 hours after MTX treatment, as indicated. Mean \pm SEM of three independent donors are shown (* P <0.05). (C) *TNFAIP3* mRNA expression on GM-MØ transfected with control siRNA (siC) or siRNA for TYMS (si8, si9) and exposed to MTX for 48 hours, as determined by qRT-PCR. Results are expressed as fold induction with MTX. Mean and SEM of six independent donors are shown (* P <0.05). (D) *TNFAIP3* expression on GM-MØ transfected with control siRNA and siRNA for TYMS and exposed to PFT (50 μ M) for 48 hours, as determined by qRT-PCR. Results are expressed as fold induction, which indicates the expression of *TNFAIP3* in siRNA TYMS-transfected relative to siRNA control cells, and untreated or treated with PFT. Mean and SEM of six independent donors are shown. FA, folinic acid; IL, interleukin; Mo, monocytes; MTX, methotrexate; PFT, pifithrin- α ; qRT-PCR, quantitative real-time PCR; RA, rheumatoid arthritis; TYMS, thymidylate synthetase.

macrophages, and clarify the molecular basis for the anti-inflammatory activity of low-dose MTX.

We also found that *TNFAIP3* mRNA expression is significantly higher in PBMCs of MTX-responsive individuals from a cohort

of patients with early arthritis under MTX monotherapy. In the context of RA, A20 is a susceptibility gene because (1) polymorphisms of the A20-coding gene *TNFAIP3* are associated with RA^{31–34} and other inflammatory diseases such as systemic lupus erythematosus and psoriasis³⁴; (2) myeloid cell-specific deletion of the *Tnfaip3* gene in mice leads to enhanced NF- κ B and inflammasome signalling and triggers a spontaneous erosive polyarthritis that resembles human RA³⁵; and (3) A20 mRNA expression in PBMCs is lower in patients with RA compared with healthy individuals.³³ The modulation of A20 by MTX that we now report supports the existence of a myeloid-specific effect of the main anchor drug in the treatment of RA and positions A20 as a potential biomarker of responsiveness to MTX, an urgently required parameter to identify those patients with early arthritis who achieve an ACR50 response to MTX monotherapy (usually around 40%).¹³ Therefore, the analysis of *TNFAIP3* polymorphism in MTX-treated patients with RA might be of interest to predict MTX responsiveness in patients with RA and could become a useful MTX response biomarker. Supporting this suggestion, a single nucleotide polymorphism within the *OLIG3/TNFAIP3* locus is associated with reduced likelihood to remain on MTX therapy in patients with early RA.³⁶

MTX is considered a prodrug, a compound that undergoes a biochemical modification to become its active form. MTX is polyglutamated once taken up by the cells and MTX polyglutamates (MTX-Pgl) constitute the active form of the drug. MTX-Pgl potently inhibits TS and aminoimidazole-carboxamide-ribonucleoside transformylase. In human macrophages, proinflammatory TS⁺ GM-CSF-primed macrophages retain higher levels of MTX-Glu₂ and MTX-Glu₃ than anti-inflammatory TS^{low/-} M-CSF-polarised macrophages and are more susceptible to MTX.¹⁷ Importantly, retention of MTX-Pgl in cells exceeds its half-life in plasma, suggesting that MTX metabolites persist in tissues. In fact, long-lived MTX-Pgl remains in the liver and in bone marrow myeloid precursors for a long period of time.³⁷ The accumulation of MTX in myeloid precursors correlates with the tolerance mechanism that we now describe because macrophages in the inflamed synovial tissue of patients with RA are continuously replaced by circulating monocytes,^{38 39} and because myeloid precursors appear to contribute to trained innate immunity.⁴⁰ We hypothesise that monocytes from MTX-treated patients would exhibit impaired responsiveness to danger signals (TNF α , RAS) and that they would display a lower proinflammatory profile than resident macrophages within the inflamed synovia. Therefore, the entry of macrophages with a lower proinflammatory potential into the inflamed synovia would contribute to the beneficial effect of MTX in RA. In any event, the involvement of A20 in MTX response provides a new mechanism of action for MTX, an old drug with low cost and a good safety record.




Figure 5 Effect of low-dose MTX on LPS tolerance in vivo. (A) Schematic representation of the experiment. C57BL/6J mice received an intraperitoneal injection of either saline or MTX (2 mg/kg). Seven days later, intraperitoneal LPS (9 mg/kg) was administered and serum collected after 4 hours for IL-6 (B) and TNF α (C) determination by ELISA. Data represent the results of two independent experiments using a total of 12 mice per group. Mean \pm SEM of 12 mice per group are shown (* P <0.05, ** P <0.01). MTX, methotrexate.




Figure 6 Effect of MTX on *TNFAIP3* mRNA expression of peripheral blood mononuclear cells from patients with early arthritis. (A) *TNFAIP3* expression along the follow-up (n=17 patients; online supplementary table S2). (B) *TNFAIP3* expression between responder and non-responder patients along the follow-up (n=17 patients). The variable that explained *TNFAIP3* expression was being responder to MTX ($P < 10^{-4}$, model 3 in online supplementary table S2). (C) *TNFAIP3* expression between responder and non-responder patients untreated or treated with MTX (n=15 visits in non-responder and n=35 visits in responder patients). MTX, methotrexate.

Acknowledgements The authors acknowledge Carlota Chiralt and Julia Villarejo for technical help in the sepsis experiments and Dr Angel L. Corbí, Dr Juan D. Cañete and Dr Paloma Sánchez-Mateos for helpful discussions.

Contributors CM and AD-S designed research, performed research and analysed data; SF-R, AL, NM, VDC and RGC performed research and analysed data; JLP participated in the research; IG-A designed research and analysed data; AP-K conceived the study, designed research, performed some research, analysed data and wrote the paper. All authors had final approval of the version.

Funding This work was supported by grants from Instituto de Salud Carlos III/FEDER (PI14/00075 and PI17/00037) to AP-K, PI14/00422 to IG-A, RIER RD16 to JLP, IG-A and AP-K, Ministerio de Economía y Competitividad SAF2014-54423-R to ALC. FEDER, Fondo Europeo de Desarrollo Regional: una manera de hacer Europa. SF-R and AP-K are supported by FIBHGM.

Competing interests None declared.

Patient consent Obtained.

Ethics approval This study was approved by Research Ethics Committee of Hospital Universitario La Princesa (PI-518).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med* 2001;344:907–16.
- Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. *Lancet* 2010;376:1094–108.
- McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med* 2011;365:2205–19.
- Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. *Arthritis Rheum* 2009;60:1210–21.
- Haringman JJ, Gerlag DM, Zwiderman AH, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. *Ann Rheum Dis* 2005;64:834–8.
- Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. *Nat Rev Rheumatol* 2016;12:37–48.
- de Vries EG, Willems PH, Biesma B, et al. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. *Lancet* 1991;338:517–8.
- Soler Palacios B, Estrada-Capetillo L, Izquierdo E, et al. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile. *J Pathol* 2015;235:515–26.
- Behrens F, Tak PP, Østergaard M, et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. *Ann Rheum Dis* 2015;74:1058–64.
- Burmester GR, Weinblatt ME, McInnes IB, et al. Efficacy and safety of mavrimumab in subjects with rheumatoid arthritis. *Ann Rheum Dis* 2013;72:1445–52.
- Burmester GR, McInnes IB, Kremer J, et al. A randomised phase IIb study of mavrimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. *Ann Rheum Dis* 2017;76:1020–30.
- Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Ann Rheum Dis* 2009;68:1086–93.
- Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. *Nat Rev Rheumatol* 2016;12:731–42.
- Kremer JM, Lawrence DA, Hamilton R, et al. Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. *RMD Open* 2016;2:e000287.
- Spurlock CF, Tossberg JT, Matlock BK, et al. Methotrexate inhibits NF- κ B activity via long intergenic (noncoding) RNA-p21 induction. *Arthritis Rheumatol* 2014;66:2947–57.
- Spurlock CF. Methotrexate-mediated inhibition of nuclear factor kappaB activation by distinct pathways in T cells and fibroblast-like synoviocytes. *Rheumatology* 2015;54:178–87.
- Municio C, Soler Palacios B, Estrada-Capetillo L, et al. Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis. *Ann Rheum Dis* 2016;75:2157–65.
- Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. *J Rheumatol* 2004;31:645–8.
- Godfrey C, Sweeney K, Miller K, et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. *Br J Clin Pharmacol* 1998;46:369–76.
- González-Álvarez I, Ortiz AM, Alvaro-Gracia JM, et al. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. *PLoS One* 2011;6:e29492.
- Joosten LA, Abdollahi-Roodsaz S, Dinarello CA, et al. Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. *Nat Rev Rheumatol* 2016;12:344–57.
- Riera-Borrull M, Cuevas VD, Alonso B, et al. Palmitate Conditions Macrophages for Enhanced Responses toward Inflammatory Stimuli via JNK Activation. *J Immunol* 2017;199:3858–69.

- 23 Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. *Trends Immunol* 2009;30:475–87.
- 24 Park SH, Park-Min KH, Chen J, *et al.* Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. *Nat Immunol* 2011;12:607–15.
- 25 Häcker H, Redecke V, Blagoev B, *et al.* Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. *Nature* 2006;439:204–7.
- 26 Nomura F, Akashi S, Sakao Y, *et al.* Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. *J Immunol* 2000;164:3476–9.
- 27 Murphy MB, Xiong Y, Pattabiraman G, *et al.* Pellino-3 promotes endotoxin tolerance and acts as a negative regulator of TLR2 and TLR4 signaling. *J Leukoc Biol* 2015;98:963–74.
- 28 Shembade N, Harhaj EW. Regulation of NF- κ B signaling by the A20 deubiquitinase. *Cell Mol Immunol* 2012;9:123–30.
- 29 Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. *Rheumatology* 2004;43:267–71.
- 30 Gossec L, Smolen JS, Ramiro S, *et al.* European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis* 2016;75:499–510.
- 31 Shen N, Ruan Y, Lu Y, *et al.* Three single nucleotide polymorphisms of TNFAIP3 gene increase the risk of rheumatoid arthritis. *Oncotarget* 2017;8:20784–93.
- 32 Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, *et al.* Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. *Arthritis Res Ther* 2009;11:R42.
- 33 Zhu L, Wang L, Wang X, *et al.* Characteristics of A20 gene polymorphisms and clinical significance in patients with rheumatoid arthritis. *J Transl Med* 2015;13:215.
- 34 Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. *Nat Rev Immunol* 2012;12:774–85.
- 35 Matmati M, Jacques P, Maelfait J, *et al.* A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. *Nat Genet* 2011;43:908–12.
- 36 Plant D, Farragher T, Flynn E, *et al.* A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register. *Pharmacogenomics J* 2012;12:128–33.
- 37 Koizumi S, Curt GA, Fine RL, *et al.* Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. *J Clin Invest* 1985;75:1008–14.
- 38 Thurlings RM, Wijbrandts CA, Bennis RJ, *et al.* Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease. *PLoS One* 2009;4:e7865.
- 39 Issekutz AC, Issekutz TB. Monocyte migration to arthritis in the rat utilizes both CD11/CD18 and very late activation antigen 4 integrin mechanisms. *J Exp Med* 1995;181:1197–203.
- 40 Netea MG, Joosten LA, Latz E, *et al.* Trained immunity: A program of innate immune memory in health and disease. *Science* 2016;352:aaf1098.